|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu
ZY, Shi W, Jiang J, Yao PP and Zhu HP: Risk factors and preventions
of breast cancer. Int J Biol Sci. 13:1387–1397. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Park M, Kim D, Ko S, Kim A, Mo K and Yoon
H: Breast cancer metastasis: Mechanisms and therapeutic
implications. Int J Mol Sci. 23:68062022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gouri A, Benarba B, Dekaken A, Aoures H
and Benharkat S: Prediction of late recurrence and distant
metastasis in early-stage breast cancer: Overview of current and
emerging biomarkers. Curr Drug Targets. 21:1008–1025. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yeo SK and Guan JL: Breast cancer:
Multiple subtypes within a tumor? Trends Cancer. 3:753–760. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mani DR, Krug K, Zhang B, Satpathy S,
Clauser KR, Ding L, Ellis M, Gillette MA and Carr SA: Cancer
proteogenomics: Current impact and future prospects. Nat Rev
Cancer. 22:298–313. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Y, Kong X, Wang Z and Xuan L: Recent
advances of transcriptomics and proteomics in triple-negative
breast cancer prognosis assessment. J Cell Mol Med. 26:1351–1362.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
du Bois H, Heim TA and Lund AW:
Tumor-draining lymph nodes: At the crossroads of metastasis and
immunity. Sci Immunol. 6:eabg35512021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arneth B: Tumor microenvironment. Medicina
(Kaunas). 56:152019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rizzo A and Ricci AD: Biomarkers for
breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin
Investig Drugs. 31:549–555. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cui Q, Dai L, Li J and Xue J: Accuracy of
CEUS-guided sentinel lymph node biopsy in early-stage breast
cancer: A study review and meta-analysis. World J Surg Oncol.
18:1122020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Karaman S and Detmar M: Mechanisms of
lymphatic metastasis. J Clin Invest. 124:922–928. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
MacLean B, Tomazela DM, Shulman N,
Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC and
MacCoss MJ: Skyline: An open source document editor for creating
and analyzing targeted proteomics experiments. Bioinformatics.
26:966–968. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tyanova S, Temu T, Sinitcyn P, Carlson A,
Hein MY, Geiger T, Mann M and Cox J: The Perseus computational
platform for comprehensive analysis of (prote)omics data. Nat
Methods. 13:731–740. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Das S and Skobe M: Lymphatic vessel
activation in cancer. Ann N Y Acad Sci. 113:235–241. 2008.
View Article : Google Scholar
|
|
16
|
Liu Z, Wang R, Zhou J, Zheng Y, Dong Y,
Luo T, Wang X and Zhan W: Ultrasound lymphatic imaging for the
diagnosis of metastatic central lymph nodes in papillary thyroid
cancer. Eur Radiol. 31:8458–8467. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cha YJ, Kim ES and Koo JS: Amino acid
transporters and glutamine metabolism in breast cancer. Int J Mol
Sci. 19:9072018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
El Ansari R, McIntyre A, Craze ML, Ellis
IO, Rakha EA and Green AR: Altered glutamine metabolism in breast
cancer; subtype dependencies and alternative adaptations.
Histopathology. 72:183–190. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim S, Kim DH, Jung WH and Koo JS:
Expression of glutamine metabolism-related proteins according to
molecular subtype of breast cancer. Endocr Relat Cancer.
20:339–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Craze ML, Cheung H, Jewa N, Coimbra NDM,
Soria D, El-Ansari R, Aleskandarany MA, Wai Cheng K, Diez-Rodriguez
M, Nolan CC, et al: MYC regulation of glutamine-proline regulatory
axis is key in luminal B breast cancer. Br J Cancer. 118:258–265.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Semenza GL: Hypoxia-inducible factors:
Coupling glucose metabolism and redox regulation with induction of
the breast cancer stem cell phenotype. EMBO J. 36:252–259. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de Heer EC, Jalving M and Harris AL: HIFs,
angiogenesis, and metabolism: Elusive enemies in breast cancer. J
Clin Invest. 130:5074–5087. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chichiarelli S, Altieri F, Paglia G,
Rubini E, Minacori M and Eufemi M: ERp57/PDIA3: New insight. Cell
Mol Biol Lett. 27:122022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hettinghouse A, Liu R and Liu CJ:
Multifunctional molecule ERp57: From cancer to neurodegenerative
diseases. Pharmacol Ther. 181:34–48. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song D, Liu H, Wu J, Gao X, Hao J and Fan
D: Insights into the role of ERp57 in cancer. J Cancer.
12:2456–2464. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park S, Park JH, Jung HJ, Jang JH, Ahn S,
Kim Y, Suh PG, Chae S, Yoon JH, Ryu SH and Hwang D: A secretome
profile indicative of oleate-induced proliferation of HepG2
hepatocellular carcinoma cells. Exp Mol Med. 50:1–14. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Y, Lin MC, Wang H, Chan CY, Jiang L,
Ngai SM, Yu J, He ML, Shaw PC, Yew DT, et al: Proteomic analysis of
EZH2 downstream target proteins in hepatocellular carcinoma.
Proteomics. 7:3097–3104. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li S, Zhao X, Chang S, Li Y, Guo M and
Guan Y: ERp57-small interfering RNA silencing can enhance the
sensitivity of drug-resistant human ovarian cancer cells to
paclitaxel. Int J Oncol. 54:249–260. 2019.PubMed/NCBI
|
|
29
|
Czarnecka AM, Synoradzki K, Firlej W,
Bartnik E, Sobczuk P, Fiedorowicz M, Grieb P and Rutkowski P:
Molecular Biology of Osteosarcoma. Cancers (Basel). 12:21302020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pitsava G, Stratakis CA and Faucz FR:
PRKAR1 and thyroid tumors. Cancers (Basel). 13:38342021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kirschner LS: PRKAR1A and the evolution of
pituitary tumors. Mol Cell Endocrinol. 326:3–7. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kochel TJ and Fulton AM: Multiple drug
resistance-associated protein 4 (MRP4), prostaglandin transporter
(PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as
determinants of PGE2 levels in cancer. Prostaglandins Other Lipid
Mediat. 116–117. 99–103. 2015.PubMed/NCBI
|
|
33
|
Huynh T, Norris MD, Haber M and Henderson
MJ: ABCC4/MRP4: A MYCN-regulated transporter and potential
therapeutic target in neuroblastoma. Front Oncol. 2:1782012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rasmuson A, Kock A, Fuskevåg OM, Kruspig
B, Simón-Santamaría J, Gogvadze V, Johnsen JI, Kogner P and
Sveinbjörnsson B: Autocrine prostaglandin E2 signaling promotes
tumor cell survival and proliferation in childhood neuroblastoma.
PLoS One. 7:e293312012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Montani M, Hermanns T, Müntener M, Wild P,
Sulser T and Kristiansen G: Multidrug resistance protein 4 (MRP4)
expression in prostate cancer is associated with androgen signaling
and decreases with tumor progression. Virchows Arch. 462:437–443.
2013. View Article : Google Scholar : PubMed/NCBI
|
